Psoriasis Treatments Show No Impact on Blood Glucose Levels: Study

Why does this matter? People with psoriasis generally run a higher risk of developing type-2 diabetes—likely tied to chronic inflammation. It’s tempting to hope that anti-inflammatory biologics or methotrexate could pull double duty by improving glucose metabolism. But this study’s data suggest otherwise: these effective skin-clearing treatments don’t seem to nudge blood sugar.

That doesn’t mean biologics aren’t valuable—they still work wonders for managing skin symptoms and overall inflammation. But for diabetics, or psoriasis patients concerned about long-term metabolic risks, it’s important to know these drugs don’t appear to offer glycemic protection.

For clinicians, this means continuing to monitor HbA1c routinely, just like in any other patient, and pushing for proven metabolic strategies—diet, exercise, medications when needed—rather than assuming psoriasis treatment alone will move the needle.

Keywords: psoriasis, biologic therapy, methotrexate, HbA1c, glucose metabolism, antidiabetic effect, Dermatology journal